Version 2 of 34 (2006-03-10 to 2006-09-22) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
Corporation: |
Sanofi Pasteur Limited
1755 Steeles Avenue West Toronto, ON M2R 3T4 Canada |
||||
Telephone number: | 416-667-2760 | ||||
Fax number: | 416-667-2977 | ||||
Responsible officer name and position during the period of this registration: | J .Mark Lievonen, President | ||||
Description of activities: | The sanofi-aventis Group is the world's third-largest pharmaceutical company, ranking number one in Europe. Backed by a world-class Research & Development organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. Sanofi pasteur, the vaccines business of the sanofi-aventis Group, sold nearly a billion doses of vaccine in 2004, making it possible to protect more than 500 million people across the globe, which is about 1.4 million per day. The company offers the broadest range of vaccines, providing protection against 20 bacterial and viral diseases. | ||||
The client is a subsidiary of the following parent companies: |
Sanofi-aventis
174 avenue de France Paris 75013 France |
||||
Coalition | The corporation is not a member of a coalition. | ||||
Subsidiary: |
Sanofi Pasteur Inc.
1 Discovery Drive Swiftwater, PA United States of America 18370 |
||||
Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. | ||||
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | Yes | ||||
End date of the corporation's last completed financial year: | 2005-12-31 | ||||
|
Name: | Luis Barreto |
Position title: | Vice President, Public Affairs |
Public offices held: | No |
Name: | J. Lievonen |
Position title: | President |
Public offices held: | No |
Name: | Jason Locklin |
Position title: | Deputy Director, Government Relations |
Public offices held: | No |
Name: | Irene Marson |
Position title: | Senior Director, Oncology Business |
Public offices held: | No |
Name: | James Tartaglia |
Position title: | Vice President, Research & Development |
Public offices held: | No |
Name: | Robert Van Exan |
Position title: | Director, Immunization Policy |
Public offices held: | No |
Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Competition Tribunal (CT), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Human Resources Development Canada (HRDC), Industry Canada, National Defence (DND), National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB), Public Works and Government Services Canada, Social Sciences and Humanities Research Council (SSHRC) | ||||
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format | ||||
Subject Matter: Areas of Concern: | Consumer Issues, Defence, Education, Government Procurement, Health, Industry, Intellectual Property, Internal Trade, International Relations, International Trade, Science and Technology | ||||
Subject Matter: Retrospective: | Contact with elected/non-elected Officials as required for ongoing business interests. | ||||
Subject Matter: Prospective: | Contact with elected/non-elected Officials as required for ongoing business interests. | ||||
Details Regarding the Identified Subject Matter
|